Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

Along with the recent approval of Moderna's next-generation covid vaccine, mNexspike, we think this puts Moderna in a good position to file for approval of both the influenza vaccine and a ...

Moderna, Inc. (MRNA) on Thursday announced that the U.S. Food and Drug Administration (FDA) has fully approved its COVID-19 vaccine Spikevax in children aged six months through 11 years who are at ...

Those limits match the terms FDA recently approved for Novavax’s shot, Nuvaxovid and Moderna’s mNexspike. Novavax’s vaccine is the only protein-based coronavirus vaccine available in the U.S ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two COVID-19 vaccines.

Those limits match the terms FDA recently approved for Novavax’s shot, Nuvaxovid and Moderna’s mNexspike.

Those limits match the terms FDA recently approved for Novavax’s shot, Nuvaxovid and Moderna’s mNexspike.

FDA staff reached a similar conclusion for the Moderna vaccine, deeming it similar in safety and effectiveness to the company’s original shot.